Dicerna Pharmaceuticals (NASDAQ:DRNA) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.
Analyst Ratings
This is a summary of current recommendations for Dicerna Pharmaceuticals and Syros Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Dicerna Pharmaceuticals | 0 | 0 | 11 | 0 | 3.00 |
| Syros Pharmaceuticals | 0 | 2 | 5 | 0 | 2.71 |
Dicerna Pharmaceuticals presently has a consensus price target of $34.20, indicating a potential upside of 32.66%. Syros Pharmaceuticals has a consensus price target of $13.2857, indicating a potential upside of 15.83%. Given Dicerna Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Dicerna Pharmaceuticals is more favorable than Syros Pharmaceuticals.
Risk and Volatility
Dicerna Pharmaceuticals has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.
Insider and Institutional Ownership
82.8% of Dicerna Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.2% of Syros Pharmaceuticals shares are owned by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are owned by company insiders. Comparatively, 14.2% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Dicerna Pharmaceuticals and Syros Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Dicerna Pharmaceuticals | -213.04% | -74.79% | -22.53% |
| Syros Pharmaceuticals | -1,950.42% | -84.15% | -50.21% |
Earnings and Valuation
This table compares Dicerna Pharmaceuticals and Syros Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Dicerna Pharmaceuticals | $23.90 million | 79.73 | $-120,460,000.00 | ($1.76) | -14.65 |
| Syros Pharmaceuticals | $1.98 million | 264.70 | $-75,440,000.00 | ($1.88) | -6.10 |
Syros Pharmaceuticals has lower revenue, but higher earnings than Dicerna Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Dicerna Pharmaceuticals beats Syros Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
